Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai expects that ARICEPT will become applicable for the treatment of severe Alzheimer's disease. Currently, ARICEPT is available in 76 countries.
The company aims for ARICEPT sales of 185 billion yen ($1.7 bil) worldwide in fiscal 2005.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Sep 3, 2005|
|Previous Article:||Asahi Kasei Chemicals Wins Orders for Membrane Bioreactor Wasterwater Treatment Plants in China.|
|Next Article:||Takara Shuzo to Adopt Biodegradable Plastic Bottle Caps for Its Products.|